A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk

A. Patel, A. Cass, D. Peiris, T. Usherwood, A. Brown, S. Jan, B. Neal, Graham Hillis, N. Rafter, A. Tonkin, R. Webster, L. Billot, S. Bompoint, C. Burch, H. Burke, N. Hayman, B. Molanus, C.M. Reid, L. Shiel, S. TogniA. Rodgers

    Research output: Contribution to journalArticle

    84 Citations (Scopus)

    Abstract

    © The European Society of Cardiology 2014. Background: Most individuals at high cardiovascular disease (CVD) risk worldwide do not receive any or optimal preventive drugs. We aimed to determine whether fixed dose combinations of generic drugs ('polypills') would promote use of such medications. Methods: We conducted a randomized, open-label trial involving 623 participants from Australian general practices. Participants had established CVD or an estimated five-year CVD risk of ≥15%, with indications for antiplatelet, statin and ≥2 blood pressure lowering drugs ('combination treatment'). Participants randomized to the 'polypill-based strategy' received a polypill containing aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12.5 mg. Participants randomized to 'usual care' continued with separate medications and doses as prescribed by their doctor. Primary outcomes were self-reported combination treatment use, systolic blood pressure and total cholesterol. Results: After a median of 18 months, the polypill-based strategy was associated with greater use of combination treatment (70% vs. 47%; relative risk 1.49, (95% confidence interval (CI) 1.30 to 1.72) p
    Original languageEnglish
    Pages (from-to)920-930
    JournalEuropean Journal of Preventive Cardiology
    Volume22
    Issue number7
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk'. Together they form a unique fingerprint.

    Cite this